Abstract:Twenty‐seven novel l‐tryptophan derivatives with strong antioxidant potential were designed and synthesized according to the reported l‐tryptophan derivatives with submicromolar butyrylcholinesterase inhibitory activity. Compounds 3a‐18 and 3b‐1 with the strongest inhibitory activity, also exhibited extraordinary antioxidant activity, inhibitory activity against β‐amyloid1–42 self‐aggregation, and low cell toxicity. Alzheimer's disease (AD) is a multifactorial neurological disease, and the multitarget directed ligand (MTDL) strategy may be an effective approach to delay its progression. Based on this strategy, 27 derivatives of l‐tryptophan, 3a‐1–3d‐1, were designed, synthesized, and evaluated for their biological activity. Among them, IC50 (inhibitor concentration resulting in 50% inhibitory activity) values of compounds 3a‐18 and 3b‐1 were 0.58 and 0.44 μM for human serum butyrylcholinesterase (hBuChE), respectively, and both of them exhibited more than 30‐fold selectivity for human serum acetylcholinesterase. Enzyme kinetics studies showed that these two compounds were mixed inhibitors of hBuChE. In addition, these two derivatives possessed extraordinary antioxidant activity in OH radical scavenging and oxygen radical absorption capacity fluorescein assays. Meanwhile, these compounds could also prevent β‐amyloid (Aβ) self‐aggregation and possessed low toxicity on PC12 and AML12 cells. Molecular modeling studies revealed that these two compounds could interact with the choline binding site, acetyl binding site, and peripheral anionic site to exert submicromolar BuChE inhibitory activity. In the vitro blood–brain barrier permeation assay, compounds 3a‐18 and 3b‐1 showed enough blood–brain barrier permeability. In drug‐likeness prediction, compounds 3a‐18 and 3b‐1 showed good gastrointestinal absorption and a low risk of human ether‐a‐go‐go‐related gene toxicity. Therefore, compounds 3a‐18 and 3b‐1 are potential multitarget anti‐AD lead compounds, which could work as powerful antioxidants with submicromolar selective inhibitory activity for hBuChE as well as prevent Aβ self‐aggregation.

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer’s disease

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of Novel Tetrahydroacridin Hybrids with Sulfur-Inserted Linkers as Potential Multitarget Agents for Alzheimer's Disease

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Development of novel chalcone derivatives as multifunctional agents for the treatment of Alzheimer's disease

Design, Synthesis and Biological Evaluation of 1-Phenyl-ethanone Derivatives for Multi-Targeted Treatment of Alzheimer's Disease

Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential anti-Alzheimer's Disease Agents.

Design, Synthesis and Biological Evaluation of New 3,4-Dihydro-2(1<i>H</i>)-Quinolinone-Dithiocarbamate Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of 2-Arylethenylquinoline Derivatives As Multifunctional Agents for the Treatment of Alzheimer's Disease.

4Dual functional antioxidant and butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of novel melatonin-alkylbenzylamine hybrids

Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.

Design, Synthesis, and Biological Evaluation of Carbamate Derivatives of N-salicyloyl Tryptamine As Multifunctional Agents for the Treatment of Alzheimer's Disease.

Design, Synthesis, and Biological Evaluation of Diosgenin-Indole Derivatives As Dual-Functional Agents for the Treatment of Alzheimer's Disease.

Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation

Design, synthesis, and activity evaluation of novel multitargeted l‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease

Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease